Hemostemix Inc. (CVE:HEM – Get Free Report) shares were up 31% during trading on Friday . The stock traded as high as C$0.23 and last traded at C$0.19. Approximately 480,687 shares changed hands during trading, a decline of 9% from the average daily volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Up 31.0 %
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a 50-day moving average of C$0.20 and a two-hundred day moving average of C$0.12. The firm has a market capitalization of C$27.69 million, a P/E ratio of -5.54 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- High Dividend REITs: Are They an Ideal Way to Diversify?
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- Health Care Stocks Explained: Why You Might Want to Invest
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
